Amar Mann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amar Mann has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Carola S. König
Department of Mechanical and Aerospace Engineering Brunel University London London UK
1 shared publication - John Marriott
School of Health Sciences College of Medicine and Health University of Birmingham Birmingham UK
1 shared publication - Malcolm James Price
University of Birmingham, Birmingham, UK
1 shared publication - Rob McFarlane
Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK
1 shared publication - Sudarshan Ramachandran
Department of Clinical Biochemistry University Hospitals Birmingham NHS Foundation Trust West Midlands UK
1 shared publication
Latest Publications
- Open Access
- 2 December 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3208
Age and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure
We believe that there is sufficient evidence from basic science, longitudinal cohort studies and randomised controlled trials which validates the low-density lipoprotein cholesterol (LDL-C) or lipid hypothesis. It is important that we can communicate details of the cardiovascular disease (CVD) risk reduction that the average patient could expect depending on the scale of LDL-C decrease following lipid lowering therapy. It is also essential that residual risk (ResR) of CVD be highlighted. To achieve this aim by using existing trial evidence, we developed mathematical models initially for relative risk reduction (RRR) and absolute risk (AR) reduction and then showed that despite optimising LDL-C levels, a considerable degree of ResR remains that is dependent on AR. Age is significantly associated with AR (odds ratio: 1.02, 95% confidence intervals: 1.01–1.04) as was previously demonstrated by analysing the Whickham study cohort using a logistic regression model (age remaining significant even when all the other significant risk factors such as sex, smoking, systolic blood pressure, diabetes and family history were included in the regression model). A discussion of a paper by Ference et al. provided detailed evidence of the relationship between age and AR, based on lifetime LDL-C exposure. Finally, we discussed non-traditional CVD risk factors that may contribute to ResR based on randomised controlled trials investigating drugs improving inflammation, thrombosis, metabolic and endothelial status.
- 2 December 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3208
Open AccessAge and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure
We believe that there is sufficient evidence from basic science, longitudinal cohort studies and randomised controlled trials which validates the low-density lipoprotein cholesterol (LDL-C) or lipid hypothesis. It is important that we can communicate details of the cardiovascular disease (CVD) risk reduction that the average patient could expect depending on the scale of LDL-C decrease following lipid lowering therapy. It is also essential that residual risk (ResR) of CVD be highlighted. To achieve this aim by using existing trial evidence, we developed mathematical models initially for relative risk reduction (RRR) and absolute risk (AR) reduction and then showed that despite optimising LDL-C levels, a considerable degree of ResR remains that is dependent on AR. Age is significantly associated with AR (odds ratio: 1.02, 95% confidence intervals: 1.01–1.04) as was previously demonstrated by analysing the Whickham study cohort using a logistic regression model (age remaining significant even when all the other significant risk factors such as sex, smoking, systolic blood pressure, diabetes and family history were included in the regression model). A discussion of a paper by Ference et al. provided detailed evidence of the relationship between age and AR, based on lifetime LDL-C exposure. Finally, we discussed non-traditional CVD risk factors that may contribute to ResR based on randomised controlled trials investigating drugs improving inflammation, thrombosis, metabolic and endothelial status.